+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.

Age: 18Years +All GendersPhase 3
318 locations
E

Actively Recruiting

Researchers are evaluating TAK-226 to see how it may improve symptoms of transfusion-dependent anemia in Japanese adults diagnosed with lower-risk myelodysplastic syndromes MDS. This Phase 2 study focuses on patients classified as very low, low, or intermediate risk according to established criteria. The study aims to assess the efficacy and safety of TAK-226, an investigational drug given by injection. During the Treatment Period, participants receive TAK-226 as a subcutaneous injection every four weeks for about one year. The study includes a Screening Period lasting up to six weeks, followed by a Safety Follow-Up Period of eight weeks after treatment ends. There is also a Long-Term Follow-Up Period lasting approximately five years from the first dose to monitor any lasting effects or side effects. Participants will visit the clinic approximately every two to four weeks during treatment. Researchers will measure outcomes such as the percentage of participants achieving transfusion independence or increases in hemoglobin levels over specific timeframes. In addition, various blood tests and safety assessments will be conducted throughout the study and follow-up periods. The total participation duration may last up to about six years.

Age: 18Years +All GendersPhase 2
21 locations
C

Actively Recruiting

Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.

Age: 18Years +All GendersPhase 3
270 locations
E

Actively Recruiting

Researchers are evaluating belimumab as an additional treatment for adults with interstitial lung disease ILD linked to connective tissue diseases CTDs such as rheumatoid arthritis, systemic lupus erythematosus, and others. ILD leads to lung inflammation and stiffness, causing symptoms like shortness of breath and cough, which significantly reduce quality of life and are the main cause of death in these patients. This study aims to see if belimumab combined with standard therapy can stabilize or improve lung function and ILD symptoms while maintaining an acceptable safety profile. Participants are randomly assigned to receive either belimumab or a placebo, both alongside standard therapy. Belimumab is given by subcutaneous injection. The study lasts for 52 weeks with treatment and monitoring occurring throughout this period. The primary measurement is the change in lung function, specifically forced vital capacity FVC, from baseline to week 52. Various secondary measures assess lung symptoms, fatigue, quality of life, lung imaging, and safety outcomes. During the study, participants will have assessments at baseline and week 52 including lung function tests, symptom questionnaires, and imaging scans. Researchers will track changes in lung capacity, disease progression, symptom severity, fatigue, and medication use. Safety monitoring continues up to week 60 to record adverse events and hospitalizations related to respiratory issues. Participants will be involved in regular visits for evaluation and medication administration over the course of the year-long study.

Age: 18Years +All GendersPhase 3
132 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
E

Actively Recruiting

Researchers are evaluating treatments for adults with multiple myeloma, a type of blood cancer that has returned or is not responding to current therapies. This Phase 2 study focuses on the drug belantamab mafodotin given less frequently alongside standard cancer medicines to see if it can effectively control the disease while reducing side effects, especially those affecting the eyes. The study also monitors overall treatment response and safety. Participants receive belantamab mafodotin combined with one of three standard regimens pomalidomide plus dexamethasone, bortezomib plus dexamethasone, or carfilzomib plus dexamethasone. The drug dosing is extended to potentially reduce side effects. The study is open-label and non-randomized, with each participant assigned to one of these three treatment combinations. During the study, participants undergo regular assessments including eye exams, tests to measure cancer response, and monitoring for side effects. The main outcome measured is the overall response rate up to about 52 months. Secondary measures include complete response rate, minimal residual disease negativity, duration of response, and detailed safety monitoring including eye-related symptoms. The study lasts until August 2030, with ongoing safety and effectiveness evaluations throughout.

Age: 18Years +All GendersPhase 2
59 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of belimumab in adults with interstitial lung disease ILD linked to systemic sclerosis SSc and other connective tissue diseases CTD. This open-label extension study follows participants from previous clinical trials to assess whether belimumab can continue to slow lung function decline, disease progression, and improve quality of life over time. Participants will receive belimumab throughout the study. The research builds on earlier randomized trials, focusing on how well the drug is tolerated over several years. The study monitors participants over approximately five years, including key assessments at baseline and during follow-up visits. During the study, participants will be regularly assessed for adverse events and changes in lung function by measuring forced vital capacity FVC at set intervals, such as weeks 12, 26, and 52. Researchers will track safety outcomes and disease progression while participants either self-administer the medication or have it given by a caregiver or healthcare professional. The total participation duration may last up to around five years.

Age: 18Years +All GendersPhase 3
41 locations
I

Actively Recruiting

Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.

All AgesAll Genders
54 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of ONO-2017 cenobamate combined with other antiepileptic drugs in Japanese patients who have primary generalized tonic-clonic seizures. This phase III, open-label study focuses on patients aged 12 years or older who experience frequent generalized seizures as part of idiopathic generalized epilepsy. Participants will take cenobamate orally once daily alongside one to three other fixed-dose antiepileptic medications. The study aims to observe changes in seizure frequency over a 12-week maintenance period while monitoring safety and tolerability. Throughout the study, researchers will track seizure frequency and reduction rates using 28-day intervals during the maintenance phase. Participants will be assessed regularly for seizure control and any side effects. The study will continue until January 2027, allowing for ongoing evaluation of treatment effects and safety.

Age: 12Years +All GendersPhase 3
25 locations

1-10 of 11

1